Aridis Pharmaceuticals Inc Quick Ratio (ARDS) starting from the third quarter 2023 to third quarter 2022, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Aridis Pharmaceuticals Inc   (NASDAQ: ARDS)

Aridis Pharmaceuticals Inc 's Quick Ratio

ARDS's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the third quarter 2023, Quick Ratio deteriorated to 0 a new company low.

Within Major Pharmaceutical Preparations industry 653 other companies have achieved higher Quick Ratio than Aridis Pharmaceuticals Inc in third quarter 2023. While Quick Ratio total ranking in the third quarter 2023 has deteriorated compared to the prior quarter from 5813 to 6258.

Explain Quick Ratio?
How much Cash & cash equivalents ARDS´s has?
What are ARDS´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ARDS Quick Ratio (Sep 30 2023)
Q3		 (Jun 30 2023)
Q2		 (Mar 31 2023)
Q1		 (Dec 31 2022)
Q4		 (Sep 30 2022)
Q3
Y / Y Current Liabilities Change -58.65 % -34.92 % 14.24 % 10.65 % 46.35 %
Y / Y Cash & cash equivalent Change -98.14 % -99.7 % -89.42 % -73.06 % -89.65 %
Quick Ratio MRQ 0 0 0.04 0.13 0.04
ARDS's Total Ranking # 6258 # 5813 # 4443 # 3822 # 4460
Seq. Current Liabilities Change -14.28 % -42.44 % -3.98 % -12.72 % 34.91 %
Seq. Cash & cash equivalent Change 84.21 % -98.56 % -72.93 % 158.54 % -70.14 %



Quick Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 654
Healthcare Sector # 1330
Overall Market # 6258


Quick Ratio Statistics
High Average Low
7.68 1.51 0
(Dec 31 2017)   (Jun 30 2023)




Financial Statements
Aridis Pharmaceuticals Inc 's Current Liabilities $ 17 Millions Visit ARDS's Balance sheet
Aridis Pharmaceuticals Inc 's Cash & cash equivalent $ 0 Millions Visit ARDS's Balance sheet
Source of ARDS's Sales Visit ARDS's Sales by Geography


Cumulative Aridis Pharmaceuticals Inc 's Quick Ratio

ARDS's Quick Ratio for the trailling 12 Months

ARDS Quick Ratio

 (Sep 30 2023)
12 Months		 (Jun 30 2023)
12 Months		 (Mar 31 2023)
12 Months		 (Dec 31 2022)
12 Months		 (Sep 30 2022)
12 Months
Y / Y Current Liabilities TTM Growth -20.13 % 8.36 % 24.81 % 27.83 % 38.25 %
Y / Y Cash & cash equivalent TTM Growth -83.88 % -85.3 % -72.51 % -49.28 % -4.3 %
Quick Ratio TTM 0.06 0.06 0.1 0.18 0.28
Total Ranking TTM # 4988 # 4890 # 4285 # 4859 # 4862
Seq. Current Liabilities TTM Growth -18.37 % -7.5 % 3.12 % 2.57 % 10.75 %
Seq. Cash & cash equivalent TTM Growth -22.85 % -43.74 % -43.65 % -34.1 % -29.64 %

Quick ratio ranking by company, industry and sector >> Back to ARDS Financial Strength Comparisons >> Go to Compare ARDS Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in ARDS's Current Liabilities to $17.48 millions, cumulative Quick Ratio to 0.06 below the ARDS average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 605 other companies have achieved higher Quick Ratio than Aridis Pharmaceuticals Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2023 from 4890 to 4988.

Explain Quick Ratio?
How much Cash & cash equivalents ARDS´s has?
What are ARDS´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 606
Healthcare Sector # 1229
Within the Market # 4988


trailing twelve months Quick Ratio Statistics
High Average Low
1 0.42 0.06
(Jun 30 2020)   (Sep 30 2023)




Companies with similar Quick Ratio in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2023 MRQ Cash & cash equivalentSep 30 2023 MRQ Current Liabilities
Orgenesis Inc 0.00 $ 0.055  Millions$ 14.302  Millions
Scienture Holdings Inc 0.00 $ 0.034  Millions$ 9.092  Millions
Novaccess Global Inc 0.00 $ 0.021  Millions$ 5.889  Millions
Celularity Inc 0.00 $ 0.273  Millions$ 84.632  Millions
REST EZ Inc. 0.00 $ 0.000  Millions$ 0.042  Millions
Biostax Corp 0.00 $ 0.010  Millions$ 4.212  Millions
REGENEREX PHARMA, INC. 0.00 $ 0.006  Millions$ 2.808  Millions
Propanc Biopharma Inc 0.00 $ 0.007  Millions$ 3.133  Millions
China Health Industries Holdings Inc 0.00 $ 0.012  Millions$ 5.961  Millions
Aridis Pharmaceuticals Inc 0.00 $ 0.035  Millions$ 17.482  Millions
Impel Pharmaceuticals Inc 0.00 $ 0.239  Millions$ 124.743  Millions
Ocean Biomedical Inc 0.00 $ 0.031  Millions$ 29.385  Millions
Aspire Biopharma Holdings Inc 0.00 $ 0.000  Millions$ 0.316  Millions

Date modified: 2026-09-18T13:11:05+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.